TAYSHAGTX.COM
3000 Pegasus Park Drive, Suite 1430
Dallas, Texas 75247 USA

April 20, 2022

Dear Batten disease community,

We are writing to provide an update on Taysha's CLN1 disease gene therapy program and the CLN7 disease gene therapy in collaboration with UT Southwestern (UTSW).

Taysha recently announced strategic pipeline prioritization initiatives to increase operational efficiency and as such, activities related to the CLN1 disease development program will be reduced. In the future, our hope is to initiate a clinical study for CLN1 disease with a limited number of patients to focus on a proof-of-concept study. At this time, the CONNECT study webinar is postponed. Development of the CLN7 program will continue in collaboration with existing partners.

"Unfortunately, we are unable to move the CLN1 program forward as rapidly as we would like and as the patient community deserves. We hope this will change in the near future. Our heartfelt thoughts are with the patients and their families affected."

-Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM,
Pediatrician, Chief Medical Officer and Head of Research & Development at Taysha Gene Therapies

We are sharing this information with you as part of our commitment to ongoing, open communication with the community and we recognize that this decision will have an impact on families in the Batten disease community. We hope to be able to provide you with an update through our advocacy partners in the near future.

If you have any additional questions, please contact medinfo@tayshagtx.com.

Sincerely,
The Taysha Team